Reserve Bank indicated. The notices also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank indicated for that notice or to the offices of the Board of Governors. Comments must be received not later than October 29, 2015.

A. Federal Reserve Bank of Kansas City (Dennis Denney, Assistant Vice President) 1 Memorial Drive, Kansas City, Missouri 64198–0001.

i. Rick Chochon, Columbus, Nebraska; B&T Capital, LLC, Columbus, Nebraska; Revocable Trust Agreement of Thomas K. Herransen and Charlene A. Herransen; Cassville, Missouri; Charlene Herransen, Cassville, Missouri, individually and as trustee of Trust; Lance Herransen, St. Libory, Nebraska; Scott Mueller, Columbus, Nebraska; Jordan Mueller, Columbus, Nebraska; Brandon Mueller, Lincoln, Nebraska; Bruce Mueller, Columbus, Nebraska; and Rod Hassebrook, Platte Center, Nebraska; to acquire shares of Rae Valley Financials, Inc., Petersburg, Nebraska, and thereby indirectly acquire Petersen State Bank, Petersburg, Nebraska.

B. Federal Reserve Bank of Dallas (Robert L. Tripplett III, Senior Vice President) 2200 North Pearl Street, Dallas, Texas 75201–2272:

1. Kent Steven McKinney and Janet Martin McKinney, as trustees of the McKinney Living Revocable Trust u/a/d 8/3/99, all of Kerrville, Texas, individually, and together with the trust constituting a “McKinney Family Control Group”; to acquire shares of Relationship Financial Corporation, and thereby indirectly acquire Guadalupe National Bank, both of Kerrville, Texas.

Board of Governors of the Federal Reserve System, October 9, 2015.

Michael J. Lewandowski, Associate Secretary of the Board.

[FR Doc. 2015–26267 Filed 10–14–15; 8:45 am]
BILLING CODE 6210–01–P

GULF COAST ECOSYSTEM RESTORATION COUNCIL

Membership of the Gulf Coast Ecosystem Restoration Council Performance Review Board

AGENCY: Gulf Coast Ecosystem Restoration Council.

ACTION: Notice of Membership on the Gulf Coast Ecosystem Restoration Council’s Performance Review Board Membership.

SUMMARY: In accordance with 5 U.S.C. 4314(c)(4), the Gulf Coast Ecosystem Restoration Council (GCERC), announce the appointment of those individuals who have been selected to serve as members of GCERC’s Performance Review Board. The Performance Review Board is responsible for reviewing performance appraisals and rating of Senior Executive Service (SES) members and making recommendations to the appointing authority on other performance management issues, such as pay adjustments, bonuses and Presidential Rank Awards for SES members. The appointment of these members to the Performance Review Board will be for a period of twenty-four (24) months.

DATES: The period of appointment for those individuals selected for GCERC’s Performance Review Board begins on October 15, 2015.

FOR FURTHER INFORMATION CONTACT: Jennifer Munz, Department of Commerce, Office of Human Resources Management, Office of Executive Resources, 14th and Constitution Avenue NW., Room 51010, Washington, DC 20230, at (202) 482–4051.

SUPPLEMENTARY INFORMATION: In accordance with 5 U.S.C. § 4314(c)(4), the Gulf Coast Ecosystem Restoration Council (GCERC), announce the appointment of those individuals who have been selected to serve as members of GCERC’s Performance Review Board. The Performance Review Board is responsible for (1) reviewing performance appraisals and rating of Senior Executive Service (SES) members and (2) making recommendations to the appointing authority on other performance management issues, such as pay adjustments, bonuses and Presidential Rank Awards for SES members. The appointment of these members to the Performance Review Board will be for a period of twenty-four (24) months.

DATES: The period of appointment for those individuals selected for GCERC’s Performance Review Board begins on October 15, 2015. The name, position title, and type of appointment of each member of GCERC’s Performance Review Board are set forth below by organization:

Department of Commerce, Office of the Secretary (OS)
Pravina Raghaven, Senior Advisor for Policy and Program Integration, Department of Commerce, Career SES, Chairperson (New Member)

Gulf Coast Ecosystem Restoration Council
Justin Ehrenwerth, Executive Director, Gulf Coast Ecosystem Restoration Council, Limited Term SES (New Member)
Mary Pfeffner, Chief Financial Officer and Director of Administration, Gulf Coast Ecosystem Restoration Council, Career SES (New Member)

Department of Agriculture
Homor Wilkes, Director Gulf Coast Restoration Division, Natural Resources Conservation Service, U.S. Department of Agriculture, Career SES (New Member)

Texas Commission on Environmental Quality, State of Texas
Stephen Tatum, Executive Assistant and Special Counsel to Commissioner Toby Baker of Texas, Texas Commission on Environmental Quality, State of Texas, (New Member)

Department of Conservation and Natural Resources, State of Alabama
Patti Powell, State Lands Director, Department of Conservation and Natural Resources, State of Alabama (New Member)

Dated: September 24, 2015.

Denise A. Yaag,
Director, Office of Executive Resources, Office of Human Resources Management, Office of the Secretary/Office of the CFO/ASA, Department of Commerce.

[FR Doc. 2015–26232 Filed 10–14–15; 8:45 am]
BILLING CODE 6560–58–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2015–N–0001]

Peripheral and Central Nervous System Drugs Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Peripheral and Central Nervous System Drugs Advisory Committee.

General Function of the Committee:
To provide advice and recommendations to the Agency on FDA’s regulatory issues.

Date and Time: The meeting will be held on November 24, 2015, from 8 a.m. to 5:30 p.m.
Location: FDA White Oak Campus, 10903 New Hampshire Ave., Bldg. 31 Conference Center, the Great Room (Rm. 1503), Silver Spring, MD 20993–0002. Answers to commonly asked questions including information regarding special accommodations due to a disability, visitor parking, and transportation may be accessed at: http://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm408555.htm.

Contact Person: Philip Bautista, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 20993–0002, 301–796–9001, FAX: 301–847–8533, PCNS@fda.hhs.gov, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area). A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the Agency’s Web site at http://www.fda.gov/AdvisoryCommittees/default.htm and scroll down to the appropriate advisory committee meeting link, or call the advisory committee information line to learn about possible modifications before coming to the meeting.

Agenda: The committee will discuss new drug application (NDA) 206031, drisapersen solution for injection, sponsored by BioMarin Pharmaceutical Inc., for the treatment of patients with Duchenne muscular dystrophy with mutations in the dystrophin gene that are amenable to treatment with exon 51 skipping as determined by genetic testing.

FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA’s Web site after the meeting. Background material is available at http://www.fda.gov/AdvisoryCommittees/Calendar/default.htm. Scroll down to the appropriate advisory committee meeting link.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person on or before November 9, 2015. Oral presentations from the public will be scheduled between approximately 12:40 p.m. and 2:40 p.m. Those individuals interested in making formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before October 30, 2015. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by November 2, 2015.

Persons attending FDA’s advisory committee meetings are advised that the Agency is not responsible for providing access to electrical outlets.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with disabilities. If you require accommodations due to a disability, please contact Philip Bautista at least 7 days in advance of the meeting.

FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site at http://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm11462.htm for procedures on public conduct during advisory committee meetings.

Notice of this meeting is given under 5 U.S.C. app. 2).

Dated: October 8, 2015.

Jill Hartzler Warner,
Associate Commissioner for Special Medical Programs.

FOR FURTHER INFORMATION CONTACT: Caitie Blood, MPH, Office of Disease Prevention and Health Promotion, U.S. Department of Health and Human Services, Attn: Public Comment, 1101 Wootton Parkway, Room LL–100, Rockville, MD 20852; fax—(240) 453–8281; or email—HP2020@hhs.gov.

SUPPLEMENTARY INFORMATION: For three decades, Healthy People has provided a comprehensive set of national 10-year health promotion and disease prevention objectives aimed at improving the health of all Americans. Healthy People 2020 objectives provide a framework by presenting a comprehensive picture of the nation’s health at the beginning of the decade, establishing national goals and targets to be achieved by the year 2020, and monitoring progress over time. The U.S. Department of Health and Human Services is soliciting the submission of written comments regarding new objectives proposed to be added to Healthy People 2020 since the fall 2014 public comment period, as well as written comments proposing new objectives to be included within existing Healthy People 2020 topic areas. Public participation helps shape Healthy People 2020, its framework, objectives, organization, and targets. Healthy People 2020 will provide opportunities for public input periodically throughout the decade to ensure that Healthy People 2020 reflects current public health priorities and public input. The updated set of Healthy People 2020 objectives will be incorporated on www.HealthyPeople.gov. This set will reflect further review and deliberation by the topic area workgroups, Federal Interagency Workgroup on Healthy People 2020, and other Healthy People 2020 stakeholders.

DATES: Written comments will be accepted until 5:00 p.m. ET on November 16, 2015.

ADDRESSES: Written comments will be accepted via an online public comment database at http://www.healthypeople.gov/2020/about/history-development/Public-Comment; by mail at the Office of Disease Prevention and Health Promotion, U.S. Department of Health and Human Services, Attn: Public Comment, 1101 Wootton Parkway, Room LL–100, Rockville, MD 20852; fax—(240) 453–8281; or email—HP2020@hhs.gov.

The U.S. Department of Health and Human Services solicits written comments regarding new objectives proposed to be added to Healthy People 2020 since the fall 2014 public comment period, as well as written comments proposing new objectives to be included within existing Healthy People 2020 topic areas. Public participation helps shape Healthy People 2020, its framework, objectives, organization, and targets. Healthy People 2020 will provide opportunities for public input periodically throughout the decade to ensure that Healthy People 2020 reflects current public health priorities and public input. The updated set of Healthy People 2020 objectives will be incorporated on www.healthypeople.gov.


Announcement of Solicitation of Written Comments on Modifications of Healthy People 2020 Objectives

AGENCY: Office of Disease Prevention and Health Promotion, Office of the Assistant Secretary for Health, Office of the Secretary, Department of Health and Human Services.

ACTION: Notice.